![]() |
|
|
Vol. 29, Issue 4, Part 2, 606-610, April 2001
Riyadh Armed Forces Hospital, Riyadh, Saudi Arabia (D.A.P.E., M.T., A.M.); and the University of Aberdeen, Aberdeen, United Kingdom (H.L.M., S.P.)
| |
Abstract |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
The scientific study of interethnic differences in responses to drugs has been extant for 80 years. Many of these differences have been described at the phenotypic level, and some have been explained by genetic factors. However, it is frequently difficult to disentangle accurately the hereditary and environmental influences in phenotypic comparisons. This is where the recent developments in knowledge of the genes responsible for drug receptors are starting to make a big impact. The beta 2 adrenoceptor is described; it has three genetic polymorphisms. The different genotypes influence responses to agonists such as albuterol (Salbutamol). New gene frequency data including those for Saudi Arabians, Indians, and Africans are shown. The expanding body of knowledge about genetic (and interethnic) variability in drug receptors is likely to be important in clinical medicine.
| |
Phenotypic Interethnic Comparisons |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
Early studies on interethnic
differences in responses to medications were made in the U.S.A. Paskind
(1921)
investigated the effect of 0.002 mg of atropine sulfate
hypodermically on 20 white and 20 colored men in Cook County Hospital,
Chicago. Initial slowing of the heart rate reaching a maximum in 10 to
15 min was observed frequently in whites but not in colored subjects
(Fig. 1; Table 1).
|
|
Chen and Poth (1929)
at Johns Hopkins (Baltimore, MD) measured the
change in the transverse diameter of the pupil after the instillation
of various mydriatics. Figure 2 shows a
typical result 1 h after 10% l-ephedrine. The action
was greatest in 10 Caucasians, intermediate in 10 Chinese, and least in
10 African Americans (Table 2).
|
|
Since those early observations, the whole science of pharmacogenetics has come into being. Many interethnic differences in drug responses have been found to be caused by differences in the metabolic biotransformations of drugs. However, there are clear pointers that this is not the whole story.
Two examples have been selected to illustrate this point.
| 1. | In an investigation of the effect of morphine on Caucasians
and Chinese, it was found that the former had significantly more respiratory depression than the latter at the same plasma morphine concentrations (Zhou et al., 1993 |
| 2. | A study by Olatunde and Evans (1982) |
| |
The Elucidatory Power of Genetic Polymorphisms |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
In the field of drug metabolism many polymorphisms have been found wherein the same alleles occur in different frequencies in different ethnic groups. In other instances, different alleles have been found in different populations. Many examples show how these discoveries have shed light on interethnic variability in responses to drugs. Now that we can examine alleles directly, the obfuscations inherent in phenotypic studies of the kind referred to above can be circumvented. This is because there has been a fairly sudden advance in our knowledge of drug receptors, and it is becoming clear that they are subject to genetic variability in a manner similar to drug-metabolizing enzymes.
| |
The Challenge of Receptors |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
As pointed out in Rang et al. (1999)
, the protein targets for drug
action on mammalian cells can be broadly divided into receptors, ion
channels, enzymes, and carrier molecules. According to Rang et al.
(1999)
, "Receptors differ from the others. They form the sensing
elements in the system of chemical communications that coordinate the
function of all the different cells in the body. The chemical
messengers being hormones, transmitter substances or other mediators
such as cytokines and growth factors".
The plethora of information accumulated in recent years can be seen in
the 1999 Receptor & Ion Channel Nomenclature Supplement published with
the March issue of TIPS (Alexander et al., 1999
). It consists of 108 pages. Our knowledge of molecular genetics makes it likely that there
are genetic variants for many of the receptors listed in this
supplement; some will be polymorphic (see Alexander et al., 1999
).
So the problem is one of selection. I have elected to concentrate on
the
2-adrenergic receptor, whose encoding gene
ADRB2 is on chromosome 5 (at 5q31-32) and which is
genetically different from the
1- and
3-adrenoceptors, whose genes are
ADRB1 and ADRB2 at 10q24-26 and 8p11-12,
respectively (see Alexander et al., 1999
).
| |
The 2-Adrenergic Receptor |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
This
2-AR1
is a typical metabotropic or 7-transmembrane-spanning receptor whose
structure has been well studied (see Reihaus et al., 1993
as reproduced
in Hall, 1996
, Fig. 1; Rang et al., 1999
, Figs. 2.3B and 2.7). This
receptor has been found to exhibit genetic polymorphisms (Reihaus et
al., 1993
), the two most important being Gly/Arg at codon 16, and
Glu/Gln at codon 27. Another polymorphism is at codon 164, but here the
frequency of variant alleles is low.
There has been much interest in the relationships between these
polymorphisms and various disorders, especially asthma (See Büscher et al., 1999), but this is not the subject of this
discussion. Here the initial focus will mainly be on how these
polymorphisms are related to the responsiveness of bronchial smooth
muscle to
-agonist drugs.
An in vitro study was carried out by Green et al. (1995)
using human
airway smooth muscle cells derived at autopsy from persons without
pulmonary disorders. The response to a test stimulus following a 24-h
exposure to isoproterenol showed that the homozygous Glu27 genotype
conferred pronounced desensitization and down-regulation. (Green et
al., 1995
, Table 2).
In vivo studies have shown
| 1. | A significantly greater degree of bronchodilator
desensitization of responses to formoterol with homozygous Gly16 than
with homozygous Arg16 asthmatics (see Tan et al., 1997 |
| 2. | In a survey of FEV1 in asthmatic
children, Martinez et al. (1997) |
| 3. | Albuterol concentrations in the blood were measured by Lima et
al. (1999) |
Other studies (discussed in detail by Lima et al., 1999
) failed to
show such a clear-cut difference between genotypes in their bronchodilation following albuterol administration. These studies probably differed because the drug was given by inhalation and the
concentration acting on the bronchial
2 AR was
variable. In the study by Lima et al. (1999)
, there was only a very
small intersubject variability of plasma albuterol concentrations.
These authors do not mention any interethnic differences in
responsiveness within a single genotype (e.g., homozygous Arg16).
| |
The 2-Adrenoceptor Polymorphisms in Different Ethnic
Groups |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
The data (published and unpublished) now available have been
tabulated by my collaborator Dr. Howard A. McLeod and are shown in
Table 3. There is a highly significant
regression of Arg16 allele frequency on Gln27 allele frequency,
which is further evidence in favor of linkage disequilibrium as
previously noted, for example, by Martinez et al. (1997)
and Dewar et
al. (1998)
.
|
The 13 data points obtained from Table 3 where there is information on both polymorphisms show wide variation and suggest the presence of two clusters, viz. Caucasians (1) and Africans and Chinese (2).
More data are available for the codon 27 than for the codon 16 polymorphism. There is a suggestion of the presence of a west-to-east cline (possibly stepped). The main conclusion, therefore, is that the Chinese and Africans have high Arg16 and Gln27 frequencies compared with Caucasians.
| |
Therapeutic Expectations |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
It might be expected that a Chinese population would require on
average a much smaller dose of
2-AR agonist to
achieve the same bronchodilatation as a Caucasian population.
Furthermore, the Chinese might desensitize more readily. However, this
may be an unwarranted assumption. The reason for caution in the
extrapolation is that the
2-AR is only the
first link in a catenary intracellular process (Fig.
3). The proteins involved in this
sequential process may be subject to genetic variation.
|
| |
Genetic Factors Influencing 2-Adrenoceptor Function
in Human Airways |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
Genetic heterogeneity has been found in G proteins. Virchow et al.
(1999)
described a C825T polymorphism in GNB3, the gene encoding the G
beta-3 subunit of heterotrimeric G proteins (OMIM 139130). The 825 T
allele, associated with the expression of a shorter splice variant (G
beta-3 subunit) gave enhanced signal transduction via pertussis
toxin-sensitive G proteins. Neutrophils containing the variant had an
enhanced chemotaxis and faster migration in response to stimulation
with interleukin 8.
A codon 19 Arg/Cys genetic polymorphism was described by McGraw et al.
(1998)
in the 19-amino acid peptide that regulates the mRNA translation
of the
2-AR molecule. This peptide is encoded by a short open reading frame termed the 5'-leader cistron (5'LC) situated 102 base pairs upstream from the
2-AR
coding block. The expression of
2-AR was 72%
higher in COS-7 cells bearing 5'LC Cys as compared with those
possessing 5'LC Arg (McGraw et al., 1998
, Fig. 4). In human airway
smooth muscle cells
2-AR expression was twice
as great in cells bearing 5'LC Cys (as compared with 5'LC Arg-bearing
cells). A linkage disequilibrium was demonstrated between the 5'LC
polymorphism and the
2-AR 16 and 27 polymorphisms described above. It seems possible that this new
polymorphism may influence the response of bronchial smooth muscle to
agonists, and it may exhibit interethnic variability.
It was pointed out by McGraw and Liggett (1997)
that the principal
mechanism of desensitization of
2-AR receptors
is phosphorylation by beta-AR kinase or other closely related G
protein-coupled receptor kinases.
Various cell types in the lung were found to have different activities
of these kinases. For example, mast cells had much more than smooth
muscle. These kinases could play a role in desensitization in vivo in
response to
2-agonists. Genetic polymorphisms
have not been described in these enzymes yet. It is quite possible that
they exist, and if so their interethnic distribution may be variable.
| |
Influence of 2 Adrenergic Receptor Polymorphisms in
Nonpulmonary Conditions |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
The
2-AR is a major lipolytic receptor in
human fat cells. With the notion that the
2-AR
polymorphisms might play a role in obesity, Large et al. (1997)
genotyped 140 women with a large variation in body fat mass. The Glu27
homozygotes had an average fat mass excess of 20 kg (Large et al.,
1997
, Table 1). Neither allele at the Arg16Gly polymorphism was linked
to obesity. An investigation of obese men did not give a similar result
(Hellstrom et al., 1999
). These findings in women will probably
stimulate further work and may be applied to the known interethnic
variability in obesity.
The codon 164 threonine/isoleucine polymorphism of
2-AR has not received much attention in humans
because of the comparative rarity of the less frequent (isoleucine)
allele. To investigate the functional significance of this polymorphism
in the myocardium, Turki et al. (1996)
prepared transgenic mice
expressing 45 times the normal endogenous
2-AR. Mice with the mutant 164 Ile and mice
with the wild-type threonine allele were studied. It was found in the
mutant mice (as compared with the wild-type mice) that in
vitro 1) the basal adenylyl cyclase activity was lower and 2)
maximal isoproterenol stimulated activity was lower. It was found that
in vivo 1) resting heart rate and dP/dt (max) were less and
2) responses to infused isoproterenol were similarly less.
Liggett et al. (1998)
determined the codon 164 polymorphism in 259 patients with advanced heart failure due to ischemic heart disease or
dilated cardiomyopathy and 212 healthy controls. The allele frequencies
did not differ between the two populations, but the 1-year survival
(Liggett et al., 1998
, Fig. 2) in the 10 heterozygous Ile 164-carrying
patients was only 42% compared with 76% for patients endowed with a
wild-type
2-AR (relative risk, 3.69;
p = 0.002). No interaction was noted with race (among other factors), but there were only 3 non-Caucasians in the 10 individuals in the Ile 164 group.
The studies briefly described above suggest that innovative therapies in many fields will have to take into account interethnic variations in receptors.
| |
Other Genetic Polymorphisms in Drug Receptors that may be of Clinical Interest |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
Alexander et al. (1999)
reveals many receptors that could be
relevant to clinical problems. Some are more attractive for
investigation than others. I will call attention to one, namely,
histamine 1 receptor HRH1 (OMIM 600167). The full structure of this
gene, which is at chromosomal localization 3p 25, has been published (DeBacker et al., 1998
).
Regarding histamine biotransformation, a C314T genetic polymorphism of
histamine N-methyl transferase has been described (Yan et
al., 1999
). The T314 variant allele was found to be more common in
asthmatics than in control subjects (allele frequencies, 0.19 versus
0.08;
2 = 12.40; p = 0.001;
odds ratio = 2.62).
It is a common observation that some people become much more sleepy than others after the usual doses of both oral and inhaled antihistaminics. It would be of interest to know whether this phenomenon is influenced by the C314T polymorphism in histamine N-methyltransferase and by allelic variants of the HRH 1 when they come to light.
| |
A Voyage of Exploration |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
We are embarked on a voyage of exploration of the unknown with
regard to the
2-AR polymorphisms. The key
requirements in the area of clinical practice will be to conduct
comparative experiments similar to those of Lima et al. (1999)
in
genotyped selected ethnic groups, e.g., Caucasians and Chinese,
preferably in the same environment. Then the influence and importance
of the polymorphisms in the two ethnic groups may be clarified.
The
2-AR is only one example wherein we happen
to know more than about most drug receptor polymorphisms. Obviously,
this is an exciting area of pharmacology and therapeutics and as yet its interethnic aspect has not received much attention.
On 23 July 1999 a survey was carried out of the ISI database for the combined terms "drug + receptor + human" for 1998 and 1999. A total of 766 article abstracts were found and examined. None dealt with any aspect of interethnic variability in receptors. So it would seem that the whole subject is ripe for development.
| |
"The Great Ocean of Truth" |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
The concept of "diathesis" has been in the minds of the
medical profession for many years (diathesis: a permanent, hereditary or acquired condition of the body which renders it liable to certain special diseases or affections; a constitutional predisposition or
tendency; Willis, 1681
). The idea was that persons with a particular constitution (often presumed to be hereditary) would be more liable than others to become ill when subjected to certain environmental influences. We are now at an interesting point in history because we
have recently acquired the technology and we are beginning to see
exactly how this interplay of genetic endowment and environmental factors works. This is true in fields other than pharmacogenetics and
ecogenetics; for example, in understanding resistance and susceptibility to infective disorders (see Levin and Newport, 1999
, who
describe mutations in the interferon gamma receptor 1 as causing
susceptibility to mycobacterial infections, and Allen et al., 1999
, who
describe resistance to cerebral malaria conferred by the presence of
southeast Asian ovalocytosis band 3).
In the elucidation of the scientific basis of practical therapeutics, it seems that now is the time to intensify the study of genetic and interethnic variability of receptors. They could be regarded as important undiscovered constituents in Newton's "great ocean of truth" ("I do not know what I may appear to the world but to myself I seem to have been only like a boy playing on the seashore, and diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, while the great ocean of truth lay all undiscovered before me").
| |
Acknowledgments |
|---|
Saad Al Harbi, Mohammed M Al Shamrani, Eileen MacCarthy, Anthony Illamas, Ben Centeno, and Rajakanna Jesuraja facilitated this work. The staff of the Medical Illustration Department, Riyadh Armed Forces Hospital prepared the figures. We are grateful to Jacqueline Pereira and Juliet Miquith for preparing this manuscript.
| |
Footnotes |
|---|
The collection of blood samples from various ethnic groups was funded by the Research and Ethical committee of the Riyadh Armed Forces Hospital (Chairman Dr. Saleh M. Al Deeb M.D., FRCP Glasgow, FRCP Edinburgh).
Send reprint requests to: Emeritus Professor David A. Price Evans, M.D., D.Sc., Ph.D., FRCP, C123 Riyadh, Armed Forces Hospital, P.O. Box 7897, Riyadh 11159, Kingdom of Saudi Arabia. E-mail: dapevans{at}kfshhub.kshrc.edu.sa
| |
Abbreviations |
|---|
Abbreviations used are: AR, adrenoceptor; 5'LC, 5'-leader cistron; FEV1, forced expiratory volume in 1 s.
| |
References |
|---|
2-Adrenergic Receptor
2-Adrenoceptor...
2-...
2 Adrenergic...
|
|---|
2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.
Am J Respir Cell Mol Biol
13:
25-33[Abstract].
2 adrenoceptor polymorphisms: Are they clinically important?
Thorax
51:
351-353
2-adrenoceptor gene polymorphism on obesity in males and in females.
J Int Med
245:
253-259[Medline].
2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.
J Clin Invest
162:
1534-1539.
2 adrenergic receptor on albuterol bronchodilator pharmacodynamics.
Clin Pharmacol Ther
65:
519-525[Medline].
2 adrenoceptor and response to albuterol in children with and without a history of wheezing.
J Clin Invest
100:
3184-3188[Medline].
2 adrenoceptor gene polymorphism, body weight and physical activity.
Lancet
353:
896[Medline].
2 adrenergic receptor in normal and asthmatic subjects.
Am J Respir Cell Mol Biol
8:
334-339.
2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics.
Lancet
350:
995-999[Medline].This article has been cited by other articles:
![]() |
K. Kim, J. A. Johnson, and H. Derendorf Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms J. Clin. Pharmacol., October 1, 2004; 44(10): 1083 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Bjornsson, J. A. Wagner, S. R. Donahue, D. Harper, A. Karim, M. S. Khouri, W. R. Murphy, K. Roman, D. Schneck, D. S. Sonnichsen, et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness J. Clin. Pharmacol., September 1, 2003; 43(9): 943 - 967. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||